Comparison of Micronized Halofantrine with Chloroquine-Antibiotic Combinations for Treating Plasmodium falciparum Malaria in Adults from Gabon

Peter G. KremsnerInternational Research Laboratory of the Albert-Schweitzer-Hospital, Landesinstitut fur Tropenmedizin, Department of Infectious Diseases, University of Vienna, BP 118 Lambarene, Gabon

Search for other papers by Peter G. Kremsner in
Current site
Google Scholar
PubMed
Close
,
Eckart WildlingInternational Research Laboratory of the Albert-Schweitzer-Hospital, Landesinstitut fur Tropenmedizin, Department of Infectious Diseases, University of Vienna, BP 118 Lambarene, Gabon

Search for other papers by Eckart Wildling in
Current site
Google Scholar
PubMed
Close
,
Lars JenneInternational Research Laboratory of the Albert-Schweitzer-Hospital, Landesinstitut fur Tropenmedizin, Department of Infectious Diseases, University of Vienna, BP 118 Lambarene, Gabon

Search for other papers by Lars Jenne in
Current site
Google Scholar
PubMed
Close
,
Wolfgang GraningerInternational Research Laboratory of the Albert-Schweitzer-Hospital, Landesinstitut fur Tropenmedizin, Department of Infectious Diseases, University of Vienna, BP 118 Lambarene, Gabon

Search for other papers by Wolfgang Graninger in
Current site
Google Scholar
PubMed
Close
, and
Ulrich BienzleInternational Research Laboratory of the Albert-Schweitzer-Hospital, Landesinstitut fur Tropenmedizin, Department of Infectious Diseases, University of Vienna, BP 118 Lambarene, Gabon

Search for other papers by Ulrich Bienzle in
Current site
Google Scholar
PubMed
Close
Restricted access

Multidrug resistance of Plasmodium falciparum is spreading throughout Africa. In Lambarene, Gabon where chloroquine-resistant malaria is prevalent, a randomized comparative trial with three regimens for treating P. falciparum malaria in adults was performed. One hundred two patients evaluated received either a new micronized formulation of halofantrine (8 mg/kg every 6 hr in three doses) (group H) or chloroquine (25 mg/kg for a 48-hr period) plus clindamycin (5 mg/kg every 12 hr in six doses) (group CCI), or chloroquine (as above) plus doxycycline (2 mg/kg every 12 hr in six doses) (group CD). All treatment regimens were well-tolerated. In group H, 100% of the patients were cured, and in group CCI, 97% of the patients were cured by day 28 of follow-up. In group CD, a significantly lower cure rate of 75% (P < 0.01) and a slower parasite clearance was observed, but only low grade (RI) resistance occurred.

Save